Filters
The presence of certain autoantibodies in patients with systemic sclerosis (SSc) is predictive of interstitial lung disease (ILD) progression, suggests a Singapore study.
Three months of romosozumab followed by 9 months of denosumab works just as well as 12 months of romosozumab for increasing bone mass in postmenopausal women at high risk of fracture, as shown in an open-label, noninferiority trial.
A novel ultrasonographic scoring model integrating precise definitions for each stage of salivary gland (SG) hypofunction addresses the clinical heterogeneity seen in patients with Sjögren disease (SjD) and demonstrates accuracy in reflecting three distinct stages of SG secretion function, reveals a study.
Quality of life (QOL) among patients with systemic lupus erythematosus (SLE) improves following CD19 chimeric antigen receptor (CAR) T cell therapy, with also helps lessen the socioeconomic burden associated with active disease, a study has shown.
Treating gout patients with urate-lowering therapy (ULT) to meet a serum urate level below 6 mg/dL within 12 months results in a reduced risk of major adverse cardiovascular events, as shown in a new user cohort study.
The use of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with erosive hand osteoarthritis is safe and well tolerated and may potentially relieve pain, particularly in those with greater synovial inflammation, according to the sham-controlled ESTIVAL trial.
New drug applications approved by US FDA as of 16-31 January 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Taking sublingual cyclobenzaprine (TNX-102 SL) at bedtime relieves fibromyalgia symptoms and improves function, a phase III study suggests.
Patients with systemic autoimmune inflammatory diseases—including systemic sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)—face an increased risk of heart failure (HF), as suggested in a retrospective study.
A post hoc analysis of the JUNIPERA study has validated the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) as a disease measure for children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (jPsA) in a prospective clinical trial setting, discriminating between active and inactive disease.
